KHPG(SZ:002773) Zheng Quan Zhi Xing·2025-06-10 04:17Group 1 - The company Chengdu Kanghong Pharmaceutical Group Co., Ltd. has approved the use of idle funds to purchase financial products up to RMB 3.8 billion, focusing on high safety and liquidity products issued by commercial banks [1] - The investment decision will be executed by the company's president or financial officer, with the finance department responsible for the specific purchases [1] - The company has previously invested a total of RMB 2.245 billion in bank principal-protected financial products over the past twelve months, which is within the authorized investment limits [11] Group 2 - The company’s subsidiaries, Chengdu Kanghong Biotechnology Co., Ltd. and Sichuan Kanghong Pharmaceutical Trading Co., Ltd., have utilized their own funds to purchase financial products [2] - The financial products purchased include structured deposits from China Bank and Chengdu Bank, with specific details on expected returns and conditions outlined [4][7] - The expected annualized return for some products is between 0.79% and 3.17%, depending on market conditions and performance indicators [2][3]